Appointment of Chief Executive Officer

AI SummaryClose X

Oxford BioDynamics Plc has appointed Richard Compton as Chief Executive Officer with immediate effect, bringing over 25 years of experience in scaling life sciences technology businesses, including significant leadership roles at Oxford Nanopore Technologies and Illumina. During his tenure at Oxford Nanopore, revenues grew from approximately £4 million to over £200 million, and at Illumina, he managed an EMEA operation that expanded from under $280 million to over $600 million. Iain Ross will transition from Executive Chairman to Non-Executive Chairman. Compton's focus will be on execution, prioritizing clinical utility, customer adoption, strategic partnerships, and disciplined resource allocation to drive value for patients, customers, and shareholders.

Disclaimer*

UK 100